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INTRODUCTION
The human intestinal tract comprises a large variety of
microorganisms, which create an ecosystem within the host
that has a major effect upon host physiology and biology (1,
2). Recent years have shown an increase in studies regarding
the influence of microorganisms on intestinal gene expres-
sion either in vivo, by colonizing germ-free mice with a
defined microbiota (3), or in vitro by determining the
interaction of bacteria with intestinal cell lines (4, 5). The
impact of the gut microbiota on the host has been clearly
demonstrated in model studies using Bacteroides thetaio-
taomicron , a predominant gut commensal bacterium, the
genome of which has been determined (6). When inoculated
into germ-free mice, B. thetaiotaomicron could elicit the
production of fucosylated glycans (Fuca1, 2Galb-glycans)
from the host via a molecular sensor FucR (7), and could
also affect the expression of several mouse genes, and
increase production of Ang4, an antimicrobial
protein, which is involved in the host defence against
pathogens (8). These examples all indicate that this
commensal gut bacterium was able to interact with its
host in a specific manner to affect formation of a particular
ecosystem.
Fermented dairy products, in particular, have long been
used to improve the composition and activity of the
intestinal microbiota. Such products do not appear to
have any health risks. Probiotics, although very similar to
starter cultures used in the fermentation of dairy products,
are usually of a different origin and are intended to survive
gastrointestinal (GI) transit (9). Probiotics have an estab-
lished safety record and several strains have been used for
long periods of time in diverse populations; therefore the
safety of these strains seems to be well established and
agreed (10). However, in order to be able to continue to
provide safe versions, particularly of novel strains, an
assessment of the intrinsic properties of probiotics is
necessary.
The intestine, and especially the colon, is heavily colo-
nized by microbes. Translocation of these microorganisms
to sites systemic to the gut poses a serious risk to the host.
A number of diseases exist whereby this situation may
occur. It would be of great benefit if probiotics could
diminish this translocation and the severity of the ensuing
disorder. The use of animal models is required to establish
the safety and efficacy of new and existing probiotic strains
for such applications (11, 12). Such models provide
information on the effect of probiotics on translocation of
members of the intestinal microbiota. Moreover, it has to be
established that the used strain should not translocate
either.
The intestinal mucosa forms the border between the
heavy colonized intestine and more sterile areas. It is
therefore of primary importance to both the microbiota
and host, and is a major target for probiotic safety and
functionality. In this article, the results from three studies
will be shown, dealing with safety-related properties of
members of the intestinal microbiota and of probiotic
bifidobacteria, and with the efficacy and safety of estab-
lished and new probiotics in relation to bacterial transloca-
tion.
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DIVERSITY OF MUCIN-DEGRADING GUT
CONSORTIA AND CHARACTERIZATION OF A
NOVEL MUCIN DEGRADER
Introduction
The GI tract is covered with a mucus layer composed of
high molecular weight glycoproteins, mucins, that can serve
as a barrier to protect the underlying epithelium from
pathogen attachment. It also serves as a source of nutrients
for commensal bacteria. The constant availability of these
host glycans provides a major growth factor for coloniza-
tion of intestinal microorganisms (13). However, on the
other hand, excessive degradation of mucin may be
considered a virulence factor, as loss of the protective
mucus layer may expose gut cells more to pathogens (14,
15). Under normal circumstances, mucin-degrading bac-
teria live in mutual coexistence with host cells and the rate
of degradation is balanced with the rate of synthesis by
goblet cells. However, a disturbance of the mucus layer has
been shown in cases of chronic inflammatory bowel disease
(IBD) such as Crohn’s disease and ulcerative colitis (16),
where the origin and the activity of bacteria are still unclear.
A link between IBD and intestinal sulphate-reducing
bacteria is suspected but not fully confirmed (17). Improved
knowledge of the microbiota, the GI tract and its mucus
would help in understanding the role of these microorgan-
isms in health and disease. Hence in the present study, by
combining culture-based and culture-independent methods,
we have described the microbiota able to utilize mucin, as
measured by growth in a medium containing mucin as
sole carbon source. The enrichments were analysed by
denaturing gradient gel electrophoresis (DGGE) of PCR-
amplified 16S ribosomal DNA (rDNA) sequences. More-
over, a novel intestinal organism was isolated and char-
acterized, Akkermansia muciniphila strain MucT, that is
able to use gastric mucin in pure culture.
Results and discussion
Fresh faecal samples were collected from six healthy
volunteers and inoculated in a basal medium containing
mucin as sole carbon source as described previously (18).
V6/V8 regions of the 16S rDNA from the faeces and
enrichment cultures were analysed by DGGE (Fig. 1) (19).
Profiles of the enrichment cultures showed a large diversity
of mucin-degrading bacteria consortium that differed
between the volunteers. However, some dominant bands
in the profiles seemed to be shared between individuals. A
clone library of each enrichment culture was constructed
from the 16S rDNA of each of the six individuals and the
predominant bands were sequenced. Major bands from
each enrichment were cloned and sequenced. This revealed
that most of the clones were related to bacterial sequences
with a homology B/97%, suggesting that they have not
hitherto been cultivated (Table I). In healthy adults, it has
been estimated that 1% of the cultivable colonic microbiota
is able to degrade host mucin using specific enzymes (20)
and the responsible bacteria were identified as strains of
Ruminococcus torques, Ruminococcus gnavus, Bifidobacter-
ium bifidum or Clostridium species. All of these are Gram-
positive strict anaerobes (21). Similarly, the majority of the
sequences obtained from the clone libraries in this study
showed that they all originated from strict anaerobic Gram-
positive bacteria. By use of serial dilution of a faecal
sample, we isolated one Gram-negative anaerobic organism,
Akkermansia muciniphila , which was highly specific for
mucin utilization (18). Analysis of the 16S rDNA (1433 bp)
gene revealed that the novel strain was related to, but
phylogenetically distinct from, organisms belonging to the
Prosthecobacter and Verrucomicrobium genera that are
members of the division Verrucomicrobia (Fig. 2) (22).
The most similar 16S rDNA sequences were 99% identical
to strain MucT, but each of these was derived from studies
of uncultured colonic bacteria: HuCA18, HuCC13 (23) and
L10-6 (24). It is the second member of the Verrucomicro-
bium division to be isolated from the gut, following
Victivallis vadensis (25). Bacteria related to Verrucomicro-
bium members have been detected in other environments
(soil, fresh water) and have also been identified in low
numbers in human faecal-derived 16S rRNA gene libraries
(23, 26, 27). We conclude that many human intestinal
bacteria participate in mucin degradation and have not been
yet cultivated.
IN VITRO SAFETY ASSESSMENT OF PROBIOTIC
BIFIDOBACTERIA
Introduction
Probiotics that are most commonly in use mainly belong to
the genera Lactobacillus and Bifidobacterium . Species of
these genera are generally regarded as safe, as indicated by
their long history of use in fermented foods and their
presence in the normal intestinal microbiota of humans
(28). However, some lactobacilli and bifidobacteria have
been associated with isolated cases of bacteraemia in
patients with reduced immune function or severe underlying
disease. It has also been suggested that the rate of
Lactobacillus infection is increasing (29), although recent
data do not support this view (30). It is uncertain if this
perceived increase is real or due to a more active search for
these organisms in clinical specimens. In most cases of
Lactobacillus and Bifidobacterium infection, the host in-
testinal microbiota is the most likely source of infection
(31). In this respect, it is important to note that bifidobac-
teria belong to the numerically dominant members of the
intestinal microbiota (32). Despite this, they are extremely
rarely involved in infections.
Although a large number of Lactobacillus and
Bifidobacterium strains have GRAS status and many strains
have a long history of safe use in foods (10), it is important
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Fig. 1. DGGE analysis of amplified V6/V8 regions of the 16S rDNA gene of faecal (F) samples (gel A) and enrichment (E) cultures on
mucin medium (gel B). M represents the DGGE marker. The bands identified from the 16S rDNA clone libraries are numbered. The origin
of the bands is presented in Table I. DNA isolation, PCR, DGGE analysis of the V6/V8 regions of 16S rDNA and sequencing analysis were
performed as described previously. PCR and DGGE of the enrichment cultures were performed as described previously (19).
Table I
Closest relatives as determined by comparative sequence analysis, level of identity with this relative, clone designation and accession no. of each
band identified in Fig. 1
n Species % bp Clones GenBank
accession no.
1 Akkermansia muciniphila 100 1433 NA AY271254
2 Ruminococcus obeum 99 522 1/21 AY451996
3 Ruminococcus obeum 95 551 1/11 AY451995
4 Ruminococcus torques 96 438 2/3 AY451997
5 Ruminococcus obeum 96 534 2/18 AY451998
6 Clostridium clostriiformes 95 978 3/1 AY451999
7 Eubacterium ramulus 99 1414 3/3 AY452000
8 Ruminococcus obeum 96 1457 3/5 AY452001
9 Ruminococcus obeum 92 1457 3/9 AY452002
10 Ruminococcus obeum 95 1457 3/10 AY452003
11 Clostridium sp. 93 1004 3/13 AY452004
12 Ruminococcus obeum 94 1457 3/16 AY452005
13 Desulfomonas pigra 99 1505 3/17 AY452006
14 Ruminococcus torques 99 1418 3/18 AY452007
15 Bacterium mpn-isolate group18 99 410 4/2 AY452008
16 Fusobacterium prausnitzii 96 543 4/9 AY452009
17 Ruminococcus productus 93 472 4/13 AY452010
18 Escherichia coli 98 502 4/17 AY452011
19 Clostridium ramosum 98 534 5/10 AY452012
20 Escherichia coli 99 533 5/12 AY452013
21 Clostridium ramosum 97 546 5/13 AY452014
22 Ruminococcus obeum 98 538 6/4 AY452015
23 Ruminococcus obeum 97 520 6/10 AY452016
24 Ruminococcus obeum 97 512 6/13 AY452017
25 Ruminococcus obeum 95 524 6/14 AY452018
26 Ruminococcus sp. CO27 96 506 6/16 AY452019
The 26 sequences of the 16S rDNA determined in this study were deposited in the GenBank database.
NA: Not applicable (Pure Culture).
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that the safety of novel and existing starter and probiotic
cultures is confirmed. As most bifidobacteria are non-
pathogenic, it is difficult to identify inherent strain proper-
ties that may be related to health risks. We therefore chose
to compare faecal, blood and probiotic Bifidobacterium
isolates for adhesion to immobilized human collagen type
IV, fibrinogen or intestinal mucus. Adhesion to the intest-
inal mucosa is one of the principal selection criteria for
probiotics (9). However, adhesion is also one of the first
steps in microbial pathogenesis (33). It is therefore im-
portant to determine whether adhesion of probiotic bifido-
bacteria to these substrata is different for faecal and clinical
blood culture isolates. These three groups of bacteria were
chosen since probiotics are usually of faecal/intestinal origin
and also the blood isolates are generally thought to be of
intestinal origin (34). Differences in adhesion between these
groups may indicate whether these properties relate to
health risks in specific populations. On the other hand,
lack of such differences would suggest that adhesion is not a
risk factor and therefore would support the safety of these
bacteria for food use.
Furthermore, resistance to serum mediated killing, a- or
b-haemolytic activity, induction of respiratory burst
in peripheral blood mononucleocytes and phosphatidylino-
sitol-specific phospholipase C (PI-PLC) activity were
determined. These properties are considered virulence
factors for a number of pathogens. Their absence or general
presence would generate information on the importance
of such properties for the safety of probiotic bifido-
bacteria (34).
Methods and materials
Faecal bifidobacteria (nine isolates) were isolated from
healthy adult volunteers, two isolates from clinical blood
cultures were obtained from patients with severe underlying
diseases (30). The bacteria were minimally subcultured to
avoid adaptation to laboratory conditions. Three probiotic
strains were isolated from products or obtained from the
producers of such products.
Adhesion to immobilized human collagen IV, fibrinogen
and intestinal mucus was performed with radiolabelled
bacteria essentially as described earlier (35). Adhesion was
expressed as the percentage of radioactivity recovered
following adhesion, relative to the radioactivity of the
bacterial suspensions added to the substrata.
Haemolysis was determined as described by Baumgartner
and co-workers (36), using human instead of sheep blood.
Serum resistance was determined as described by Burns and
Hull (37). The induction of respiratory burst was basically
performed as described by Lilius and Marnila (38) and
expressed as mV/100 000 peripheral blood mononucleocytes
(PMN). Phosphatidylinositol-specific phospholipase C (PI-
PLC) activity was determined as described by Rodriguez
and co-workers (39). Appropriate positive and negative
controls were included in the assays, which were all
performed in triplicate.
Results
Adhesion to human mucus, collagen and fibrinogen varied
substantially for all three groups of bifidobacteria, ranging
from B/1% to almost 12%. Because of a large variation
Fig. 2. Phylogenetic tree showing the position of Akkermansia muciniphila (underlined) among selected clones or strains belonging to the
Verrucomicrobia division. The tree, which was rooted by using Escherichia coli as the outgroup, was generated by the neighbour-joining
method. Bold type indicates the clones or isolates that originated from intestinal or similar anaerobic ecosystems. Phylogenetic analyses were
performed with the ARB software package (22). Bar represents 10% sequence divergence.
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within the three groups, statistical analyses (Kruskal-Wallis,
p/0.05) did not reveal significant differences (Fig. 3) (34).
For the bifidobacteria tested a positive correlation was
observed for the adhesion to collagen and fibrinogen
(Spearman rank correlation coefficient, pB/0.0005).
None of the Bifidobacterium strains tested exhibited a- or
b-haemolysis of human blood group O erythrocytes.
With the exception of one faecal B. longum isolate, all
strains tested were found to be resistant to serum-mediated
killing. Of the 14 Bifidobacterium strains tested, 12 were
found to grow in the presence of 80% human serum. All
strains survived and grew in heat-inactivated serum.
The respiratory burst induced in PMN varied from 287 to
20 000 mv/100 000 PMN. There was a trend (p/0.083) for
dairy strains to induce a stronger respiratory burst,
although this did not reach statistical significance (Fig. 4).
None of the tested strains exhibited PI-PLC activity.
Discussion
In the current study, we investigated the adhesion of
bifidobacteria isolated from probiotic products, blood and
faeces, to human intestinal mucus, collagen and fibrinogen.
No statistically significant differences could be observed in
the adhesive properties between the three groups to any of
the three substrata tested. Therefore, it seems unlikely that a
specific selection of probiotic bifidobacteria with high
adhesive capacities to the intestinal mucosa poses any risk
to the consumer. The observed positive correlation in
adhesion to the tested extracellular matrix proteins suggests
that similar adhesins may be used for adhesion to these
substrata. This would, however, require further investiga-
tion.
None of the bifidobacteria tested exhibited haemolytic
activity, this may be due to the fact that bifidobacteria do
not require iron for their growth (40). Therefore, haemolysis
does not appear to be a potential risk factor for bifido-
bacteria. Although all except one of the tested bifidobac-
teria were resistant to serum-mediated killing, this does not
seem to be a risk but rather an intrinsic property of
bifidobacteria. In general, Gram-positive bacteria are not
sensitive to the complement system present in serum. An
inability to induce a respiratory burst in PMN may enhance
the survival, after translocation, of a bacterium in the
blood. Although the clinical isolates exhibited a lower
induction of respiratory burst, this was not significant.
Based on these observations, this point does warrant further
investigation. PI-PLC activity has been suggested to be
associated with translocation of lactobacilli, although this
was tested for only two strains of L. rhamnosus (39).
However, this activity was absent from all strains tested,
also the clinical isolates, and is therefore not likely to be a
relevant risk factor for probiotic bifidobacteria.
Thus, no properties have so far been identified that may
generate a concern for the consumption of probiotic
lactobacilli and bifidobacteria. As no general risk factors
were found to be associated with the clinical lactobacilli
and bifidobacteria, this may indicate that the condition of
the patient contributed more to translocation than did
the properties of the bacteria. However, it cannot be
excluded that other properties not yet tested could be
involved.
Further in vitro studies to assess the importance of more
potential risk factors need to be carried out. From such
studies, strains that possess more risk factors will be used in
animal trials to correlate in vitro findings to the in vivo
situation (41). Studies as described above are also being
performed with lactobacilli, for which larger numbers of
strains are available.
The ultimate safety test is always a human feeding trial.
Existing probiotic bifidobacteria have a long history of safe
use and some of the emerging strains have successfully been
assessed for their in vivo safety in humans (42).
In conclusion, the findings of the studies described here
support the general view that probiotic bifidobacteria are
wholly safe for human consumption.
Fig. 3. Adhesion of bifidobacteria of probiotic, faecal and clinical
(blood) origin to immobilized human intestinal mucus, human
collagen IV and human fibrinogen. Results are expressed as the
average of three independent experiments, error bars indicate the
standard deviation (modified after (34)).
Fig. 4. Induction of respiratory burst by bifidobacteria of probio-
tic, faecal and clinical (blood) origin in peripheral blood mono-
nucleocytes. Results are expressed as the average of three
independent experiments, error bars indicate the standard deviation
(modified after (34)).
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BACTERIAL TRANSLOCATION
Introduction
The ‘gut origin of sepsis’ hypothesis proposes that bacteria,
which are normally resident within the lumen of the
intestinal tract, translocate across a damaged intestinal
epithelial barrier and act as a source of sepsis at distant sites
(43, 44). Animal studies support this concept (11, 12). Most
bacterial infections in critically ill or immunocompromised
patients are caused by the patients’ own microbiota, and
many persons dying from sepsis or multiple system organ
failure have enteric bacteraemia for which no septic focus
can be identified (44, 45). A number of factors have been
shown to predispose towards bacterial translocation. These
include shock with reduced splanchnic blood flow, parent-
eral nutrition, intestinal epithelial damage and antibiotic
therapy (12). Intestinal bacterial overgrowth (46), intestinal
atrophy and increased gut permeability (47) are all believed
to result in an escape of bacteria (48) and endotoxin (49)
from the intestinal lumen to the mesenteric lymph nodes
and portal circulation, where they stimulate peritoneal,
intestinal and hepatic macrophages to release inflammatory
mediators. Hepatic macrophages (Kupffer cells) appear to
play a role in clearance of translocated bacteria or
endotoxin from the portal circulation. Impairment of the
activity may potentiate the systemic effects of gut barrier
failure (44).
Experimental rat models
A set of bacterial strains has been tested in two experi-
mental rat models, i.e. a colitis model and a liver failure
model. The test strains were Lactobacillus plantarum 299v
(a probiotic strain originating from healthy human colonic
mucosa; Probi AB, Lund), Lactobacillus paracasei 8700:2 (a
probiotic strain with ability to grow in ripening cheese;
originating from healthy human intestinal mucosa; Probi
AB), Lactobacillus gasseri 5B3 (originating from healthy
human vagina), Bifidobacterium 3B1 (originating from
healthy human vagina) and Bifidobacterium infantis
CURE19 (a probiotic strain originating from infant faeces;
Probi AB).
Colitis model
Mucosal barrier dysfunction is a feature of colitis irrespec-
tive of aetiology or species. Such dysfunction may be
responsible for the systemic inflammatory response and
complications seen in patients with inflammatory bowel
disease (IBD) (50). The indigenous intestinal microbiota
and an intact mucosa are vital components of the body
defence against luminal pathogenic bacteria. Disruption of
these defences in IBD may permit bacterial translocation
and contribute to disease severity (51). The pathogenesis of
IBD remains unknown. Genetic and environmental factor
contributions are evident, and the luminal microbiota plays
a major role in the initiation and perpetuation of chronic
IBD (52). The effect of colonic inflammation on intestinal
microbiota, specifically lactobacilli and bifidobacteria, is
not clear.
We investigated the effect of different Lactobacillus and
Bifidobacterium strains administered orally for 7 days
before induction of colitis and continued for 7 days with
dextran sulphate sodium (DSS) (5% in drinking water). The
colitis lesions induced by DSS resemble those of human
ulcerative colitis both symptomatically and histologically.
We found that bacterial translocation to mesenteric lymph
nodes decreased significantly in all treatment groups
compared with a colitis control. Moreover, translocation
of Enterobacteriaceae to the liver decreased in all treatment
groups. Thus, administration of certain strains of Lactoba-
cillus and Bifidobacterium significantly improves the disease
activity index (DAI) and reduces bacterial translocation in a
rat model. L. plantarum 299v, Bifidobacterium 3B1 and
Bifidobacterium infantis CURE-19 seemed to have the best
effect.
Liver injury model
Liver function, the intestine and the immune system not
only influence each another, but are also affected by
nutrients and their route of delivery (53). The gut is a
major reservoir for bacteria and under normal conditions a
series of local and systemic protective mechanisms prevents
passage of pathogenic bacteria beyond the intestinal lumen,
and these defence mechanisms are severely impaired in the
acute liver injury induced by D-galactosamine (54). In-
testinal microbiota composition is important in physiologi-
cal and pathophysiological processes in the human
gastrointestinal tract. Septic complications represent fre-
quent causes of morbidity in liver diseases and following
hepatic operations.
We therefore studied the effect of different Lactobacillus
and Bifidobacterium strains on bacterial translocation,
extent of liver injury and intestinal microbiota in an acute
liver injury model. Sprague-Dawley rats were used and
Lactobacillus and Bifidobacterium strains were adminis-
tered orally twice daily for 8 days. Liver injury was induced
on the eighth day by intraperitoneal injection of
D-galactosamine (1.1 g/kg body weight). Samples were
collected 24 h after the induction of liver injury. Liver
enzymes and bilirubin serum levels, bacterial translocation
and intestinal microbiota were evaluated.
We found that administration of different Lactobacillus
and Bifidobacterium strains in an acute liver injury model
has different effects on bacterial translocation and hepato-
cellular damage. L. plantarum 299v and B. infantis CURE-
19 reduced bacterial translocation and hepatocellular
damage. L. gasseri 5B3 reduced bacterial translocation
but did not show significant effects on hepatocellular
damage. L. paracasei did not reduce bacterial translocation
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and hepatocellular damage, but translocated to extraintest-
inal sites. This clearly indicates the strain specificity of the
health effects of lactobacilli and bifidobacteria.
CONCLUSIONS
Within the intestinal microbiota new members with new
functions continue to be identified. Their role in the health
and disease of the host remains to be fully elucidated. The
studies described above have shown that the intestinal
mucosa is an important habitat and provides energy for
members of the intestinal microbiota. The barrier function
provided by the intestinal mucosa can be safely strength-
ened by selected probiotics. Through investigating the
interaction between members of the intestinal microbiota
and probiotics, new insights may be obtained on the
mechanisms by which the latter exert their health benefits.
This, together with studies on the intrinsic properties of
probiotics, is likely to lead to the development of new safe
applications for probiotics.
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